Brainstorm Cell Therapeutics Inc. (Nasdaq: BCLI) reported positive
results from a Phase 2a clinical trial of its amyotrophic lateral
sclerosis treatment NurOwn but the stock price surged last week in
anticipation of the results. Shares of the biotechnology company plunged $1.58 to $5.92.
Profit taking sinks Brainstorm Cell Therapeutics
January 05, 2015 at 12:12 PM EST
